US capacity deal with Biogen Idec part of Eisai's global production re-jig
This article was originally published in Scrip
Eisai is continuing to shake out its worldwide manufacturing operations with a decision to lease out and possibly divest to Biogen Idec part of its production facilities in Research Triangle Park (RTP) in the US.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.